title: [Evaluation of the clinical efficacy and the safety of salmeterol/fluticasone propionate accuhaler compared to budesonide turbuhalar in the control of adult asthma].
abstract: OBJECTIVE
  To evaluate the efficacy and the safety of low dose salmeterol/fluticasone (SM/FP) combination therapy as compared to morate dose of budesonide (BUD) in the management of adult asthma.
  
  
  METHODS
  A multicentre, randomised, open-label, parallel-group, 6-week treatment study was conducted. 398 patients (18 - 70 years) were given SM/FP (50/100 microg) twice daily via Accuhaler or BUD 400 microg twice daily via Turbuhaler.
  
  
  RESULTS
  The morning and the evening peak expiratory flow (PEF) measurements both increased significantly (P < 0.01) in the SM/FP group, and the increase was greater than that in the BUD group. The significant benefit of SM/FP was evident from the first week. SM/FP led to a more significant reduction in the use of rescue medication and in the day- and night-time asthma symptom scores, as compared to budesonide. Both treatments were well tolerated, and the adverse reactions showed no significant difference between the two groups.
  
  
  CONCLUSIONS
  Combination use of low doses of SM/FP is a better choice for the control of asthma. The addition of a low-dose long-acting beta(2) agonist is superior to the simple increase of the dosage of inhaled corticosteroids.
authors.affiliation: Guangzhou Institute of Respiratory Diseases, First Affiliated Hospital, Guangzhou Medical College, Guangzhou 510120, China.
authors.forename: Nan-shan
authors.initials: NS
authors.lastname: Zhong
authors.forename: Jing-ping
authors.initials: JP
authors.lastname: Zheng
authors.forename: Bai-qiang
authors.initials: BQ
authors.lastname: Cai
authors.forename: Can-mao
authors.initials: CM
authors.lastname: Xie
authors.forename: Tie-ying
authors.initials: TY
authors.lastname: Sun
authors.forename: Dan-qi
authors.initials: DQ
authors.lastname: Wang
authors.forename: Yan-ping
authors.initials: YP
authors.lastname: Lin
authors.forename: Bao-yuan
authors.initials: BY
authors.lastname: Chen
authors.forename: Jia-ju
authors.initials: JJ
authors.lastname: Tao
authors.forename: Jian
authors.initials: J
authors.lastname: Kang
authors.forename: Qiang
authors.initials: Q
authors.lastname: Li
authors.forename: Yi-ping
authors.initials: YP
authors.lastname: Xu
authors.forename: Xin
authors.initials: X
authors.lastname: Zhou
authors.forename: Xue-jun
authors.initials: XJ
authors.lastname: Guo
authors.forename: Xiao-dong
authors.initials: XD
authors.lastname: Chen
authors.forename: Kai-sheng
authors.initials: KS
authors.lastname: Yin
authors.forename: De-ping
authors.initials: DP
authors.lastname: Zhang
authors.forename: Jian-ying
authors.initials: JY
authors.lastname: Zhou
authors.forename: Hua-hao
authors.initials: HH
authors.lastname: Shen
authors.forename: Chen
authors.initials: C
authors.lastname: Qiu
authors.forename: Yu-lin
authors.initials: YL
authors.lastname: Feng
authors.forename: Bang-rong
authors.initials: BR
authors.lastname: Xiao
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000420:Albuterol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000730:Androstadienes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy*; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D019819:Budesonide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D000068298:Fluticasone; D006801:Humans; D008297:Male; D008875:Middle Aged; D011208:Powders; D000068299:Salmeterol Xinafoate; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000730:Androstadienes; D001993:Bronchodilator Agents; D011208:Powders; D019819:Budesonide; D000068299:Salmeterol Xinafoate; D000068298:Fluticasone; D000420:Albuterol